European Companies Search Engine
EU funding (€217,076): TArgeting Multiphosphorylated tau in Blood for non-invasive Alzheimer's Disease diagnosis and staging Hor29 Apr 2025 EU Research and Innovation programme "Horizon"
Overview
Text
TArgeting Multiphosphorylated tau in Blood for non-invasive Alzheimer's Disease diagnosis and staging
Alzheimer's disease (AD) is the major cause of dementia. The disease has an escalating impact on public health due to an increasing prevalence among the aging population in Europe and globally. In light of the first disease-modifying therapies becoming available, early diagnosis and precise disease staging are crucial for timely implementation of the treatment strategy. In TAMBO-AD, I will build on my preliminary findings to leverage AD biomarker potential of tau simultaneously phosphorylated at two distinct sites. By combining my expertise in immunoassay development with the top technology available at the host institution, I will develop three novel Single Molecule Array (Simoa®) assays targeting p-tau217&231, p-tau205&217, and p-tau205&231. Through cerebrospinal fluid and plasma measurements in the Amsterdam Dementia Cohort, I will evaluate performance of all three p-tau forms as: 1) early diagnostic and 2) disease-staging biomarkers. For the best-performing plasma biomarkers, I will translate Simoa® assays into innovative fiber optic nanogold-linked immunosorbent assay format (FONLISA), which enables point-of-care testing. New point-of-care testing assays will maximize biomarker testing accessibility, enabling use in primary care centers and in remote or resource-limited areas. Finally, I will communicate the project and disseminate results in English and Polish during an intersectoral secondment at the patient organization — Alzheimer Europe. The TAMBO-AD project represents a pivotal opportunity to advance my research, grow professional network, and gradually become an independent researcher.
Funded Companies:
| Company name | Funding amount |
| Alzheimer Europe | ? |
| STICHTING AMSTERDAM UMC | €217,076 |
Source: https://cordis.europa.eu/project/id/101210445
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Alzheimer Europe, Senningerberg, Luxembourg.
The visualizations for "Alzheimer Europe - EU funding (€217,076): TArgeting Multiphosphorylated tau in Blood for non-invasive Alzheimer's Disease diagnosis and staging"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
